BioRestorative Therapies
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
BioRestorative Therapies has raised $300k across 2 rounds. Its most recent round was a Series Unknown in Dec 2022. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
BioRestorative Therapies is featured in
Similar companies
AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum
Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.
Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.
Solarea Bio is a biotech company focused on developing microbial therapeutics to treat chronic inflammatory conditions and improve human health. They specialize in researching and creating natural-based therapeutics to address chronic inflammation, providing hospitals with effective medicinal options. By studying genomic sequences of microbes found in healthy foods, Solarea is able to create combinations of bacteria, fungi, and prebiotic fibers that have strong anti-inflammatory properties to target specific chronic illnesses. Their research has been tested in lab and animal studies, with their first application designed to help manage metabolic processes that lead to osteopenia and osteoporosis in postmenopausal women. Founded in 2017 in Cambridge, Massachusetts by Eric Schott, Gerardo Toledo, and Jillian DeWalt, Solarea Bio offers a natural solution to improve women's health and well-being.
Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs.
VST Bio is a biotechnology company that offers and develops treatment for vascular diseases.
Gate Bioscience is a biotech company that is developing a new type of medicine called Molecular Gates. These drugs are small molecules that selectively remove harmful extracellular proteins from inside the cell, where they originate. There are more than 4,000 extracellular proteins produced by humans, and over 1,000 of them can cause diseases when they function incorrectly. Molecular Gates aim to eliminate these disease-causing proteins, thereby eradicating the associated diseases for patients. The mechanism of action for Molecular Gates is unique, as they bind to a single channel in the cell through which extracellular proteins pass when they are secreted. By creating a "gate" in this channel, the Molecular Gates can block and recognize specific disease-causing proteins, preventing their exit from the cell. Consequently, the harmful proteins are degraded by the cell rather than being secreted. Gate Bioscience's mission to develop Molecular Gate medicines is supported by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. For more information, visit www.gatebio.com.
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
iQure Pharma is a biotechnology company founded by entrepreneurs and ex-pharmaceutical executives that specializes in creating innovative treatments on a global scale.
Clever Carnivore is cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.
The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Leveraging advanced fermentation to produce functional and nutritional proteins from microorganisms, the Company is reimagining the factory farm model that underpins industrial animal agriculture with a more sustainable, kinder, and healthier alternative. Clara Foods is on a mission to decouple the world's most powerful proteins from the animals that make them.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.